Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer
2021 · Lung Cancer · 55 citations
https://doi.org/10.1016/j.lungcan.2021.08.015
K
Kenji Morimoto
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
218
Papers
4.3K
Citations
27
h-index
73
i10-index
Kenji Morimoto is an academic researcher from Kyoto Prefectural University of Medicine. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Diet, Metabolism, and Disease & Pancreatic and Hepatic Oncology Research. The author has an h-index of 27, co-authored 186 publications.
ORCID: 0000-0003-3394-1838Papers by this author
worksImmune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study
2021 · Frontiers in Oncology · 38 citations
https://doi.org/10.3389/fonc.2021.630136
l-Xylose and l-lyxose production from xylitol using Alcaligenes 701B strain and immobilized l-rhamnose isomerase enzyme
2005 · Enzyme and Microbial Technology · 33 citations
https://doi.org/10.1016/j.enzmictec.2005.01.027
Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer
2024 · Cancer Letters · 18 citations
https://doi.org/10.1016/j.canlet.2024.217124
Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study
2022 · Frontiers in Oncology · 13 citations
https://doi.org/10.3389/fonc.2022.904644
A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC
2022 · JTO Clinical and Research Reports · 10 citations
https://doi.org/10.1016/j.jtocrr.2022.100388
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat